Broncus Holding

Broncus Holding Current Liabilities

The Current Liabilities of Broncus Holding (2216.HK) as of Nov 5, 2026 is 5.35 M USD. In the previous year, Current Liabilities was 11.31 M USD — a change of -52.72% (lower).

Current Liabilities

5.35 MUSD

YoY

-52.72%

Last updated:

Current Liabilities of Broncus Holding is 2025 5.35 M USD. Current Liabilities of Broncus Holding was 2024 11.31 M USD. It decreases by -52.72% lower compared to the previous year.

The Broncus Holding Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
15.75 M USD
Jan 1, 2020
15.40 M USD
Jan 1, 2021
14.49 M USD
Jan 1, 2022
13.72 M USD
Jan 1, 2023
15.88 M USD
Jan 1, 2024
11.31 M USD
Jan 1, 2025
5.35 M USD
The Broncus Holding Current Liabilities history
YEARCurrent LiabilitiesYoY
5.35 MUSD-52.72%
11.31 MUSD-28.77%
15.88 MUSD+15.75%
13.72 MUSD-5.38%
14.49 MUSD-5.85%
15.40 MUSD-2.22%
15.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Broncus Holding Stock analysis

What does Broncus Holding do? Broncus Holding Corp generates revenue through the sale of medical device and consumable products across multiple therapeutic areas. The company's diagnostic solutions include FleXNeedle, ATV Sheath, and ATV Balloon, targeting healthcare providers for diagnostic procedures. Lung cancer treatment solutions feature InterVapor for lung cancer and H-Marker, sold to hospitals and oncology centers. Chronic obstructive pulmonary disease (COPD) solutions consist of InterVapor for COPD and TLD Ablation System, marketed to respiratory care facilities. Navigation platforms like Lungpoint, Lungpro, and New Generation Navigation Platform are supplied to medical institutions requiring advanced imaging guidance. The firm's product portfolio is structured around four key solution areas: diagnostics, lung cancer treatment, COPD management, and navigation systems. Diagnostic tools such as FleXNeedle and ATV products are used in minimally invasive procedures, while InterVapor serves dual purposes for both lung cancer and COPD applications. The TLD Ablation System is specifically designed for COPD treatment, and navigation platforms support precise procedural guidance in respiratory interventions. Broncus Holding Corp's primary customers are healthcare institutions including hospitals, specialized oncology centers, and respiratory care facilities. These entities purchase the company's medical devices and consumables for clinical use in treating respiratory conditions. The company's commercialization strategy focuses on direct sales to medical facilities rather than through third-party distributors, ensuring consistent product application and support. Broncus Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Broncus Holding stock

Current Liabilities of Broncus Holding is 5.35 M USD in 2025.

Current Liabilities of Broncus Holding changed from 11.31 M USD to 5.35 M USD, representing a -52.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Broncus Holding since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Broncus Holding historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Broncus Holding

All Key Metrics — Broncus Holding